FDA approves Juvmo for adults with Parkinson's disease
The approval introduces a selective dopamine D1/D5 receptor partial agonist as a new oral treatment option for adults with Parkinson's disease.
Juvmo (tavapadon) has been approved by the FDA for the treatment of Parkinson's disease in adults.
The approval follows the Phase III TEMPO clinical programme and brings a selective dopamine D1/D5 receptor partial agonist into the US Parkinson's treatment landscape.
Field | Content |
Field | Content |
Alert Type | FDA Approval |
Product | Juvmo (tavapadon) |
Indication | Parkinson's disease |
Patient Population | Adults |
Technology/Modality | Oral selective dopamine D1/D5 receptor partial agonist |
Regulator | U.S. Food and Drug Administration |
Regulatory Status | FDA approved |
Clinical Programme | Phase III TEMPO programme |
What Happened | FDA approved Juvmo for the treatment of Parkinson's disease in adults. |
Why It Matters | The approval introduces a new oral treatment using selective partial agonism of dopamine D1 and D5 receptors. |
Supporting Evidence | The regulatory programme was supported by the Phase III TEMPO studies. |
Therapeutic Area | Neurology |
Potential Impact | Juvmo adds another pharmacological option for the management of Parkinson's disease in adults. |
Key Takeaway | Juvmo brings a selective D1/D5 receptor partial agonist to the US Parkinson's disease market. |
What to Watch | Commercial launch, prescribing uptake and positioning within existing Parkinson's treatment pathways. |
Primary Source | U.S. Food and Drug Administration |
Relevant Date | 25 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios